Rotavirus is the most common cause of severe gastroenteritis in infants and young children worldwide. Rotavirus causes approximately half a million deaths each year among children aged <5 years, with >80% of deaths occurring in developing countries (1). In the United States during the prevaccine era, rotavirus gastroenteritis resulted in relatively few childhood deaths (approximately 2060 deaths per year among children aged <5 years) (2--5). However, before initiation of the rotavirus vaccination program in 2006, nearly every child in the United States was infected with rotavirus by age 5 years; the majority had gastroenteritis, resulting annually during the 1990s and early 2000s in approximately 410,000 physician visits, 205,000272,000 emergency department (ED) visits, 55,00070,000 hospitalizations, and total annual direct and indirect costs of approximately $1 billion (5--9) (Figure 1). This report presents the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of two rotavirus vaccines among U.S. infants: RotaTeq® (RV5) (Merck and Company, Whitehouse Station, New Jersey), which was licensed by the Food and Drug Administration (FDA) in February 2006 (10) and Rotarix® (RV1) (GlaxoSmithKline [GSK] Biologicals, Rixensart, Belgium), which was licensed by FDA in April 2008 (11). This report updates and replaces the 2006 ACIP statement for prevention of rotavirus gastroenteritis (12).
Background
Clinical and Epidemiologic Features of Rotavirus Disease in the Prevaccine Era
In the prevaccine era, rotavirus infected almost all children by age 5 years; severe dehydrating gastroenteritis caused by rotavirus occurred primarily among children aged 423 months (13--15). Rotavirus infects the proximal small intestine, where it elaborates an enterotoxin and destroys the epithelial surface, resulting in blunted villi, extensive damage, and shedding of massive quantities of virus in stool (13). The estimated incubation period for rotavirus diarrheal illness is <48 hours (16). Under experimental conditions, adults who became ill had symptoms 1--4 days after receiving rotavirus orally (17,18). The clinical spectrum of rotavirus illness in children ranges from mild, watery diarrhea of limited duration to severe diarrhea with vomiting and fever than can result in dehydration with shock, electrolyte imbalance, and death (19). The illness usually begins with acute onset of fever and vomiting, followed 24--48 hours later by frequent, watery stools (20,21). Up to one third of children with rotavirus illness have a temperature of >102ºF (>39ºC) (22,23). Vomiting usually lasts <24 hours; other gastrointestinal symptoms generally resolve in 37 days. Rotavirus protein and ribonucleic acid (RNA) have been detected in blood, organs, and cerebrospinal fluid, but the clinical implications of these findings are not clear (20,24).
Rotaviruses are shed in high concentrations (i.e., 1012 virus particles per gram of stool during the acute illness) in the stools of infected children before and several days after clinical disease (25). Rotavirus is transmitted primarily by the fecal-oral route, both through close person-to-person contact and through fomites (26). Very few infectious virions are needed to cause disease in susceptible hosts (25). Spread is common within families. Of adult contacts of infected children, 30%50% become infected, although infections in adults often are asymptomatic because of immunity from previous exposure (27--29). Transmission of rotavirus through contaminated water or food is likely to be rare (30,31). Transmission through airborne droplets also has been hypothesized but remains unproven (21,30,32).
In the United States, rotavirus causes winter seasonal peaks of gastroenteritis, with activity beginning usually in the southwestern states during DecemberJanuary moving across the country, and ending in the northeastern states in AprilMay (33--35). Rotavirus might account for up to 10% of gastroenteritis episodes among children aged <5 years (36). Infants and children with rotavirus gastroenteritis are likely to have more severe symptoms than those with nonrotavirus gastroenteritis (22,23,37,38). In the prevaccine era, rotavirus accounted for 30%50% of all hospitalizations for gastroenteritis among U.S. children aged <5 years and up to 70% of hospitalizations for gastroenteritis during the seasonal peak months (7,14,39--44). Of all the rotavirus hospitalizations that occurred among children aged <5 years in the United States during the prevaccine era, 17% occurred during the first 6 months of life, 40% by age 1 year, and 75% by age 2 years (Figure 2). Rotavirus accounted for 20%--40% of outpatient clinic visits during the rotavirus season (14,45,46). Before the initiation of the rotavirus vaccination program, four of five children in the United States had rotavirus gastroenteritis by age 5 years (36,39,47), one in seven required a clinic or ED visit, one in 70 were hospitalized, and one in 200,000 died from this disease (3,8). Active, population-based surveillance from early 2006 and before vaccine was used provided annual rotavirus hospitalization and ED visit rates of 22.4 and 301 per 10,000 children aged <3 years, respectively (14). Rotavirus also was an important cause of hospital-acquired gastroenteritis among children (48).
In a recent study, factors associated with increased risk for hospitalization for rotavirus gastroenteritis among U.S. children included lack of breastfeeding, low birth weight (a likely proxy for prematurity), daycare attendance, the presence of another child aged <24 months in the household, and either having Medicaid insurance or having no medical insurance (49). Another study identified low birth weight, maternal factors (e.g., young age, having Medicaid insurance, and maternal smoking), and male gender as risk factors for hospitalization with viral gastroenteritis (50). These studies suggest that preterm infants are at higher risk for severe rotavirus disease. Children and adults who are immunocompromised because of congenital immunodeficiency or because of bone marrow or solid organ transplantation sometimes experience severe or prolonged rotavirus gastroenteritis (51--56). The severity of rotavirus disease among children infected with human immunodeficiency virus (HIV) might be similar to that among children without HIV infection (57). Whether the incidence rate of severe rotavirus disease among HIV-infected children is similar to or greater than that among children without HIV infection is not known. http://www.mededsys.com/product_info.php?cPath=1&products_id=239